Background/Aims: Cognitive impairment is common in hemodialysis patients and may be impacted by multiple patient and treatment characteristics. The impact of dialysis dose on cognitive function remains uncertain, particularly in the current era of increased dialysis dose and flux. Methods: We explored the cross-sectional relationship between dialysis adequacy and cognitive function in a cohort of maintenance hemodialysis patients. Adequacy was defined as the average of the 3 most proximate single pool Kt/V assessments. A detailed neurocognitive battery was administered during the 1st hour of dialysis. Multivariable linear regression models were adjusted for age, sex, education, race and other clinical and demographic characteristics. Results: Among 273 patients who underwent cognitive testing, the mean (SD) age was 63 (17) years and the median dialysis duration was 13 months, 47% were woman, 22% were African American, and 48% had diabetes. The mean (SD) Kt/V was 1.51 (0.24). In univariate, parsimonious and multivariable models, there were no significant relationships between decreased cognitive function and lower Kt/V. Conclusion: In contrast to several older studies, there is no association between lower Kt/V and worse cognitive performance in the current era of increased dialysis dose. Future studies should address the longitudinal relationship between adequacy of dialysis and cognitive function to confirm these findings.

Keywords:
Cognitive function, Dialysis adequacy, Chronic kidney disease
1.
Murray AM, Tupper DE, Knopman DS, Gilbertson DT, Pederson SL, Li S, Smith GE, Hochhalter AK, Collins AJ, Kane RL: Cognitive impairment in hemodialysis patients is common. Neurology 2006;67:216–223.
2.
Pereira AA, Weiner DE, Scott T, Chandra P, Bluestein R, Griffith J, Sarnak MJ: Subcortical cognitive impairment in dialysis patients. Hemodial Int 2007;11:309–314.
3.
Sehgal AR, Grey SF, DeOreo PB, Whitehouse PJ: Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis 1997;30:41–49.
4.
Madero M, Gul A, Sarnak MJ: Cognitive function in chronic kidney disease. Semin Dial 2008;21:29–37.
5.
Pereira AA, Weiner DE, Scott T, Sarnak MJ: Cognitive function in dialysis patients. Am J Kidney Dis 2005;45:448–462.
6.
Uzu T, Kida Y, Shirahashi N, Harada T, Yamauchi A, Nomura M, Isshiki K, Araki S, Sugimoto T, Koya D, Haneda M, Kashiwagi A, Kikkawa R: Cerebral microvascular disease predicts renal failure in type 2 diabetes. J Am Soc Nephrol 2010;21:520–526.
7.
McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M: The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501–1510.
8.
Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ: Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis 2006;47:131–138.
9.
Bremer BA, Wert KM, Durica AL, Weaver A: Neuropsychological, physical, and psychosocial functioning of individuals with end-stage renal disease. Ann Behav Med 1997;19:348–352.
10.
Kurella M, Chertow GM, Luan J, Yaffe K: Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 2004;52:1863–1869.
11.
Kurella M, Luan J, Yaffe K, Chertow GM: Validation of the Kidney Disease Quality of Life (KDQOL) cognitive function subscale. Kidney Int 2004;66:2361–2367.
12.
Kurella M, Yaffe K, Shlipak MG, Wenger NK, Chertow GM: Chronic kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis 2005;45:66–76.
13.
Yaffe K, Ackerson L, Kurella Tamura M, Le Blanc P, Kusek JW, Sehgal AR, Cohen D, Anderson C, Appel L, Desalvo K, Ojo A, Seliger S, Robinson N, Makos G, Go AS: Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc 2010;58:338–345.
14.
Hart RP, Pederson JA, Czerwinski AW, Adams RL: Chronic renal failure, dialysis, and neuropsychological function. J Clin Neuropsychol 1983;5:301–312.
15.
Umans JG, Pliskin NH: Attention and mental processing speed in hemodialysis patients. Am J Kidney Dis 1998;32:749–751.
16.
Kutlay S, Nergizoglu G, Duman N, Atli T, Keven K, Erturk S, Ates K, Karatan O: Recognition of neurocognitive dysfunction in chronic hemodialysis patients. Ren Fail 2001;23:781–787.
17.
Pliskin NH, Yurk HM, Ho LT, Umans JG: Neurocognitive function in chronic hemodialysis patients. Kidney Int 1996;49:1435–1440.
18.
Tamura MK, Larive B, Unruh ML, Stokes JB, Nissenson A, Mehta RL, Chertow GM: Prevalence and correlates of cognitive impairment in hemodialysis patients: the frequent hemodialysis network trials. Clin J Am Soc Nephrol 2010;5:1429–1438.
19.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
20.
Uttl B: North American adult reading test: age norms, reliability, and validity. J Clin Exp Neuropsychol 2002;24:1123–1137.
21.
Tulsky D, Zhu K, Lebetter M: Wechsler Adult Intelligence Scale-Third Edition (WAIS-III), Wechsler Memory Scale-Third Scale (WMS-III): Technical Manual. San Antonio, Harcourt Brace and Company, 1997.
22.
Heaton RK, Grant I, Matthews CG: Comprehensive Norms for an Expanded Halstead-Reitan Battery. Odessa, Psychological Assessment Resources, 1991.
23.
Tobin J: Estimation for relationships with limited dependent variables. Econometrica 1958;26:24–36.
24.
Elangovan L, Shinaberger CS, Kraut JA, Shinaberger JH: Hemo equilibrated Kt/V goals are difficult to achieve in large male patients. ASAIO J 2001;47:235–239.
25.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010–2019.
26.
Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG: Dose of hemodialysis and survival: differences by race and sex. JAMA 1998;280:1764–1768.
27.
Salahudeen AK, Fleischmann EH, Bower JD: Impact of lower delivered Kt/V on the survival of overweight patients on hemodialysis. Kidney Int 1999;56:2254–2259.
28.
Chertow GM, Owen WF, Lazarus JM, Lew NL, Lowrie EG: Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999;56:1872–1878.
29.
Salahudeen AK, Dykes P, May W: Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients. Nephrol Dial Transplant 2003;18:1339–1344.
30.
Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, Kasiske BL, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Li Q, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers PW, Agodoa L: Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 2010;55:S1–420, A426–A427.
31.
Murray AM, Pederson SL, Tupper DE, Hochhalter AK, Miller WA, Li Q, Zaun D, Collins AJ, Kane R, Foley RN: Acute variation in cognitive function in hemodialysis patients. A cohort with repeated measures. Am J Kidney Dis 2007;50:270–278.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.